Clinical Trial Update: The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population

View source ↗

Summary

Clinical trial update evaluating the NGAL Test as an aid to risk-stratify acute kidney injury (stages II–III) in an intensive care population.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Snippet

Sponsor: BioPorto Diagnostics | Conditions: Kidney Injury | Status: UNKNOWN